Sees FY 22 revenue $538M consensus $538.3M.2022."2022 was a year of meaningful milestones and consistent execution towards our mission of extending survival in some of the most aggressive forms of cancer," said William Doyle, Novocure’s Executive Chairman. "The successful LUNAR study marks the beginning of a transformational period where we anticipate final data from multiple pivotal trials. We are eager to reach these clinical milestones and energized by the prospect of treating tens of thousands of patients who could benefit from Tumor Treating Fields." Cash, cash equivalents and short-term investments were $969.4 million as of December 31; As of December 31, 2022, there were 3,430 active patients on therapy. Active patients from North America, EMEA and Japan contributed 2,191, 870, and 369, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVCR:
- Medicare paying 9% more for Novocure’s Optune system in 2023, says Piper
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Novocure downgraded to Equal Weight from Overweight at Wells Fargo
- Novocure price target raised to $140 from $100 at H.C. Wainwright
- NVCR, ZLAB Skyrocket as NSCLC Study Meets Primary Endpoint